Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23030377 | 0.93 | HCRTR2 (0.43) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5933504 | 0.85 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6121700 | 0.83 | POLB (0.46) | ALDH1A1POLBMAPTTP53 | |
| SCHEMBL24418213 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2AALDH2 | |
| SCHEMBL6122081 | 0.81 | ALDH1A1 (0.52) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5933496 | 0.81 | ALDH1A1 (0.48) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5932788 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5932794 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6122171 | 0.79 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL825321 | 0.78 | LMNA (0.57) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135517-A1 | METHOD OF PRODUCING CARBONYL COMPOUND AND FLOW TYPE REACTION SYSTEM OF PRODUCING CARBONYL COMPOUND | FUJIFILM CORPORATION (JP) | 2022-05-05 | — | — | US | disclosed |
| WO-2021033504-A1 | METHOD FOR PRODUCING CARBONYL COMPOUND AND FLOW REACTION SYSTEM USED FOR PRODUCTION OF CARBONYL COMPOUND | 富士フイルム株式会社 | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135517-A1 | METHOD OF PRODUCING CARBONYL COMPOUND AND FLOW TYPE REACTION SYSTEM OF PRODUCING CARBONYL COMPOUND | PARG, PTGIS, MT-ATP8 | ALDH1A1 2022/4885LMNA 3322/4885SMN1; SMN2 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.